Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells

International Journal of Radiation Biology

Volumn 83, Issue 1, 2007, Pages 41-47

  Rave Fränk, Margret ^a,d   Schmidberger, Heinz ^c   Christiansen, Hans ^a   Boll, Christine ^a   Lehmann, Jörg ^b   Weiss, Elisabeth ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Cervical cancer; Cisplatin; Lung cancer; Oxaliplatin; Radiation; Radiotherapy

Indexed keywords

CISPLATIN; ELOXANTIN; OXALIPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; COLONY FORMING UNIT; CYTOTOXICITY; DATA ANALYSIS; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOLECULAR MODEL; PRIORITY JOURNAL; RADIATION DOSE; TUMOR CELL; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 33847072642     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000601121108     Document Type: Article

References (25)

1. Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, Cascini LG, Morrica B, Lastoria S, Parisi V, Budillon A, Comella P. 2006. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: A phase I-II study. British Journal of Cancer 94:1809 -1815.
2. Belani CP. 2004. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Seminars in Oncology 31:25 -33.
3. Borch RF. 1987. The platinum anti-tumour drugs. In: Powis G, Prough RA, editors. Metabolism and action of anti-cancer drugs. London: Taylor & Francis. pp 163 -193.
4. Caney C, Singh G, Lukka H, Rainbow AJ. 2004. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. International Journal of Radiation Biology 80:291-299.
5. Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT. 2002. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. International Journal of Radiation Oncology Biology Physics 52:1092-1098.
6. Dewit L. 1987. Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. International Journal of Radiation Oncology Biology Physics 13:403-426.
7. Espinosa M, Martinez M, Aguilar JL, Mota A, De la Garza JG, Maldonado V, Melendez-Zajgla J. 2005. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemotherapy and Pharmacology 55:301-305.
8. Galanski M, Jakupec MA, Keppler BK. 2005. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Current Medical Chemistry 12:2075-2094.
9. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC. 2006. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology (ESMO) 17:50-56.
10. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ. 2001. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. The Lancet 358:781-786.
11. Greene MH. 1992. Is cisplatin a human carcinogen. Journal of the National Cancer Institut 84:306-312.
12. Groen HJ, Sleijfer S, Meijer C, Kampinga HH, Konings AW, De Vries EG, Mulder NH. 1995. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. British Journal of Cancer 72:1406-1411.
13. Haller DG. 2004. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology 31:10-16.
14. Kartalou M, Essigmann JM. 2001. Mechanisms of resistance to cisplatin. Mutation Research 478:23-43.
15. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. 2002. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. Journal of Clinical Oncology 20:2844-2850.
16. Kjellstrom J, Kjellen E, Johnsson A. 2005. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncologica 44:687-693.
17. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. 2002. Chemoradiation of cervical cancer cells: Targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Research 62:7364-7371.
18. Leblanc JM, Raaphorst P. 2005. Evaluation of cisplatin treatment given concurrently with pulsed irradiation in cisplatin sensitive and resistant human ovarian carcinoma cell lines. International Journal of Radiation Biology 81:429-435.
19. Muggia FM. 2004. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Seminars in Oncology 31:17-24.
20. Nakamoto S, Mitsuhashi N, Takahashi T, Sakurai H, Niibe H. 1996. An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. International Journal of Radiation Biology 70:747-753.
21. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD. 1999. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. British Journal of Cancer 79:1104-1110.
22. Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. 2006. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. Journal of Clinical Oncology 24:2557-2562.
23. Sanderson BJS, Ferguson LR, Denny WA. 1996. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutation Research - Fundamental Molecular Mechanisms of Mutation 355:59-70.
24. Schmidt W, Chaney SG. 1993. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Research 53:799-805.
25. Steel GG. 1979. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology Physics 5:1145-1150.